You are here
Foamix Pharmaceuticals to Participate in the Cantor Fitzgerald Global Healthcare Conference
REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary, topical therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will provide a corporate update at the Cantor Fitzgerald Global Healthcare Conference, taking place October 1-3 at the InterContinental New York Barclay Hotel.
|Cantor Fitzgerald Global Healthcare Conference 2018|
|Date:||Tuesday, October 2|
|Time:||12:15pm Eastern Time|
|Location:||InterContinental New York Barclay Hotel|
Foamix is a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary, innovative and differentiated topical drugs for dermatological therapy. Our leading clinical stage product candidates are FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne and FMX103, our novel minocycline foam for the treatment of rosacea. We continue to pursue research & development of our proprietary, innovative foam technologies for the treatment of various skin conditions. We currently have development and license agreements relating to our technology with various pharmaceutical companies including LEO Pharma A/S, as assignee to our license with Bayer HealthCare, and others.
Foamix uses its website (www.Foamix.com) as a channel to distribute information about Foamix and its product candidates from time to time. Foamix may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Foamix’s website in addition to following its press releases, filings with the Securities & Exchange Commission (“SEC”), public conference calls, and webcasts.
Ilan Hadar, CFO & Country Manager
Foamix Pharmaceuticals Ltd.
US Investor Relations
LifeSci Advisors, LLC